- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02032381
Prospective Study of Belated Pulmonary Complications Occurring in Children Treated With Allogeneic Hematopoietic Stem Cells. (RESPPEDHEM)
Prospective Study of Late Pulmonary Complications Occurring in Children Treated With Allogeneic Hematopoietic Stem Cells.
Study Overview
Status
Conditions
Detailed Description
It's a multicenter prospective study in France. All children under 18 years are included, just before the HSCT. The functional test before the HSCT at 6, 12, 18, 24, 30 and 36 months will be collected and a cardiopulmonary exercise test is done one and three years after the HSCT. Thoracic tomodensitometry is done before the HCT and after at 6, 12, 24 and 36 months.
All data will be collected upon the HSCT, the infections before and after the HSCT, the respiratory symptoms, and the treatment. Bronchia alveolar lavage and serum will be collected and frozen during the study.
The inclusion will be done during two years and children will be following during three years.
The purpose is to evaluate the prevalence, the course of PFT abnormalities before and after transplant, and to detect risk factor for PC.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75019
- Houdouin véronique
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: from birth to 18 years
- Patient to be treated by allogeneic hematopoietic stem cell - Parents who have given their signed consent for the study
- Affiliation to a social security scheme
Exclusion Criteria:
- non exclusion criteria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SCREENING
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: allogeneic hematopoietic stem cell
The eligible population for this study will consist of all children under 18 years who received allogeneic hematopoietic stem cell and evaluate of late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Presence of belated non-infectious pulmonary complications
Time Frame: 3 years
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Presence of risk factors for belated non-infectious pulmonary complications
Time Frame: 3 years
|
3 years
|
Survival three years
Time Frame: 3 years
|
3 years
|
Severity of respiratory disease
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Houdouin Véronique, MD PHD, APHP
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P120137
- 2013-A00966-39 (OTHER: APHP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchiolitis Obliterans
-
University Hospital, Basel, SwitzerlandRecruitingBronchiolitis Obliterans Syndrome (BOS) | Bronchiolitis Obliterans (BO)Switzerland, Saudi Arabia
-
Renovion, Inc.RecruitingPre-Bronchiolitis Obliterans SyndromeUnited States
-
Children's Hospital Medical Center, CincinnatiRecruitingBronchiolitis Obliterans (BO) | Hematopoietic Stem Cell Transplant (HSCT)United States
-
Washington University School of MedicineThe Foundation for Barnes-Jewish Hospital; Mallinckrodt; Centers for Medicare...Active, not recruitingBronchiolitis Obliterans Syndrome (BOS)United States
-
University of ChicagoCompletedBronchiolitis Obliterans SyndromeUnited States
-
Zambon SpATerminatedStem Cell Transplant Complications | GVHD, Chronic | Bronchiolitis Obliterans Syndrome (BOS)Spain, France, Germany
-
University Hospital RegensburgClinAssess GmbHUnknownSteroid-refractory Bronchiolitis ObliteransGermany
-
KU LeuvenUniversity Hospital, Gasthuisberg; Fund for Scientific Research, Flanders,...CompletedGraft Rejection | Respiratory Infection | Bronchiolitis Obliterans Syndrome | Lymphocytic BronchiolitisBelgium
-
Hopital FochCompletedBronchiolitis Obliterans SyndromeFrance
-
Zambon SpAEnrolling by invitationBronchiolitis Obliterans | Bronchiolitis Obliterans Syndrome | Obliterative BronchiolitisFrance, United States, Spain, Israel, Belgium, Denmark, Germany, United Kingdom, Austria
Clinical Trials on late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.
-
European Inter-group Cooperation on Childhood and...UnknownLymphomaFrance, United Kingdom, Germany, Italy, Belgium, Switzerland, Austria, Czech Republic, Ireland, Netherlands, Poland, Sweden
-
National Cancer Institute (NCI)Canadian Cancer Trials GroupActive, not recruitingAcute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeUnited States, Canada, Israel, Puerto Rico